64P Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with solid tumors and cardiac metastases
(2022) the ESMO Immuno-Oncology Congress 2022 — Location: (Switzerland) Geneva (7.December.2022)
Files
2023_Immunooncol_Technol_Nassar_64P.pdf
Open Access - Adobe PDF
- 104.89 KB
Details
- Authors
- Abstract
- Background : Incidence of cardiac metastasis (mets) is rising among pts with cancer. Data on the safety and clinical outcomes of ICIs on pts with cardiac mets is limited. [...]
- Affiliations
Citations
Nassar, A. H., Zarif, T., Abou Alaiwi, S., Denu, R., Macaron, W., El-Am, E., Malvar, C., Ocejo Gallegos, J. A., Cortellini, A., Korolewicz, J. A., Sackstein, P., Aboubakar Nana, F., Foderaro, S., Baena Espinar, J., Woodford, R., Grynberg, S., Asnani, A., Hayek, S., Choueiri, T. K., & Naqash, A.-R. (2022). 64P Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with solid tumors and cardiac metastases. Immuno-Oncology and Technology, 16(Suppl 1), 100169. https://doi.org/10.1016/j.iotech.2022.100169 (Original work published 2022)